Filing Details
- Accession Number:
- 0001567619-22-001462
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-01-21 18:16:53
- Reporting Period:
- 2022-01-19
- Accepted Time:
- 2022-01-21 18:16:53
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1829802 | Sensei Biotherapeutics Inc. | SNSE | () | DE |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1797409 | Cambrian Biopharma Inc | 19 Morris Avenue Brooklyn Navy Yard, Building 128 Brooklyn NY 11205 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2022-01-19 | 10,244 | $4.97 | 4,995,876 | No | 4 | P | Direct | |
Common Stock | Acquisiton | 2022-01-20 | 20,000 | $5.17 | 5,015,876 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct | |
No | 4 | P | Direct |
Footnotes
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.90 to $5.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.
- These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.10 to $5.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set herein.